The country’s drug administration has been directed to test samples of the free medicines that are used to treat patients at community clinics, after allegations were raised against substandard drugs being supplied by a public drug manufacturer.
On March 25, the Directorate General of Drug Administration (DGDA) received a letter of request from Makhduma Nargis, an additional secretary and the director of community clinic project, to assess the quality of the drugs supplied to the community clinics by Essential Drug Company Limited (EDCL).
The letter also read that members of the steering committee on community clinic, headed by the health secretary, had unanimously decided on testing the sample of medicines.
Selim Barami, a director of the DGDA, confirmed about receiving the letter and told the Dhaka Tribune that the drugs administration would carry out quality tests after collecting random medicine samples from the stock that was ready to be supplied to community clinics.
The health ministry reportedly spends more than Tk100 crore each year to distribute free medicine among the poor patients of community clinics across the country.
At present, community clinics offer 30 drugs including few antibiotics free-of-cost.
During the last four fiscal years, medicine worth Tk406 crore had been used for treating around 15 crore community clinic patients.
The Dhaka Tribune has learnt that although millions of taka has been spent for buying the medicines, the DGDA – which is the legal authority for checking medicine quality – had never carried out any laboratory test to assess the quality of the procured drugs for community clinics.
Seeking anonymity, a health ministry official said there was no doubt about the excellent quality of medicines manufactured by the EDCL, which had been supplying over 70% drugs to all public health hospitals and institutes.
However, as the EDCL was suffering from excess workload, it recently issued a subcontract to a private company with poor reputation for manufacturing some of the medicines for community clinics, the official claimed.
Several community clinic officials, preferring to stay unnamed, told the Dhaka Tribune that different clinics across the country had raised complaints over the past few months against the substandard quality of EDCL’s medicine.
Mukduma Nargis, director of the community clinic project, however said no compromise was ever made with the quality of medicine supplied at community clinics.
Saying her letter to the DGDA was “nothing serious,” she added that the steering committee had decided on a random check to ensure the quality of drugs.
Replying to a query on EDCL’s subcontract, Nargis said the deal was made as the public drugs manufacturer had been facing excessive workload. Quality control officers, however, were always checking the drug quality before the medicines were supplied to community clinics.
Despite repeated attempts by the Dhaka Tribune, the CEO of the EDCL, M Kadrul Huda, was not available for comments.
Currently, 12,527 independent community clinics have been running at the root-level under the project “Revitalization of Community-based Healthcare in Bangladesh.”
Community clinics help provide the basic healthcare packages to the people, including maternal and child healthcare, reproductive health and family planning services, immunisation, nutrition education, micronutrient supplementation, health education and counselling, communicable disease control, treatment for minor ailments and first aid.



